This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ZIOPHARM Oncology, Inc.
Drug Names(s): Oral palifosfamide, Oral Zymafos, Oral ZIO-201
Ziopharm is developing an oral formulation of palifosfamide for pediatric and outpatient use. Please see Zymafos for the IV formulation.
Palifosfamide is a stabilized IPM (isophosphoramide mustard). IPM is a proprietary stabilized metabolite of ifosfamide. Ifosfamide is a structural analogue of cyclophosphamide and its mechanism of action is presumed to be identical. The main effect of cyclophosphamide is due to its metabolite phosphoramide mustard. Phosphoramide mustard forms DNA crosslinks between and within DNA strands. This leads to cell death.
Oral Palifosfamide News
Additional information available to subscribers only: